This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Niludipine
Accession Number
DB09240
Type
Small Molecule
Groups
Experimental
Description

Niludipine is a calcium channel blocker.

Structure
Thumb
Synonyms
Not Available
External IDs
BAY A 7168
Categories
UNII
9844OS3B0J
CAS number
22609-73-0
Weight
Average: 490.553
Monoisotopic: 490.231516063
Chemical Formula
C25H34N2O8
InChI Key
VZWXXKDFACOXNT-UHFFFAOYSA-N
InChI
InChI=1S/C25H34N2O8/c1-5-10-32-12-14-34-24(28)21-17(3)26-18(4)22(25(29)35-15-13-33-11-6-2)23(21)19-8-7-9-20(16-19)27(30)31/h7-9,16,23,26H,5-6,10-15H2,1-4H3
IUPAC Name
3,5-bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
[H]N1C(C)=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCOCCC)=C1C)C(=O)OCCOCCC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Niludipine.Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Niludipine.Approved, Vet Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Niludipine.Investigational
AlclometasoneThe metabolism of Niludipine can be decreased when combined with Alclometasone.Approved
AlcuroniumNiludipine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Niludipine.Approved, Investigational
Aminosalicylic AcidNiludipine may increase the anticoagulant activities of Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Niludipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Niludipine.Approved
AmlodipineAmlodipine may increase the bradycardic activities of Niludipine.Approved
AmobarbitalThe metabolism of Niludipine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Niludipine.Approved
Amphotericin BNiludipine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Niludipine can be decreased when combined with Amprenavir.Approved, Investigational
ApalutamideThe serum concentration of Niludipine can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Niludipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Niludipine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Niludipine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Niludipine.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Niludipine.Approved
AtazanavirThe metabolism of Niludipine can be decreased when combined with Atazanavir.Approved, Investigational
AtracuriumNiludipine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateNiludipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzithromycinThe metabolism of Niludipine can be decreased when combined with Azithromycin.Approved
BarbexacloneThe metabolism of Niludipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Niludipine can be increased when combined with Barbital.Illicit
BetaxololThe risk or severity of bradycardia can be increased when Niludipine is combined with Betaxolol.Approved, Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Niludipine.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Niludipine.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Niludipine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Niludipine.Approved
BoceprevirThe metabolism of Niludipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Niludipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Niludipine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Niludipine.Approved, Investigational
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Niludipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Niludipine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Niludipine.Investigational
ButalbitalThe metabolism of Niludipine can be increased when combined with Butalbital.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Niludipine.Approved
CabergolineThe metabolism of Niludipine can be decreased when combined with Cabergoline.Approved
CalcitriolThe metabolism of Niludipine can be increased when combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Phosphate.Approved
CarbamazepineThe metabolism of Niludipine can be increased when combined with Carbamazepine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Niludipine.Approved, Investigational
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Niludipine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Niludipine.Approved, Investigational, Nutraceutical, Vet Approved
CeritinibThe serum concentration of Niludipine can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Niludipine can be decreased when combined with Cevimeline.Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Niludipine.Approved, Investigational, Vet Approved
CholecalciferolThe metabolism of Niludipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Niludipine can be increased when it is combined with Cimetidine.Approved, Investigational
CisatracuriumNiludipine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe metabolism of Niludipine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Niludipine can be decreased when combined with Clarithromycin.Approved
Clobetasol propionateThe metabolism of Niludipine can be increased when combined with Clobetasol propionate.Approved
ClonidineClonidine may increase the bradycardic activities of Niludipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niludipine.Approved
ClotrimazoleThe metabolism of Niludipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Niludipine.Approved
CobicistatThe metabolism of Niludipine can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Niludipine.Approved, Investigational
CrizotinibThe metabolism of Niludipine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Niludipine can be decreased when combined with Curcumin.Approved, Investigational
CyclosporineThe metabolism of Niludipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Niludipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Niludipine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Niludipine.Approved, Investigational, Withdrawn
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Niludipine.Approved
DapsoneThe metabolism of Niludipine can be decreased when combined with Dapsone.Approved, Investigational
DarunavirThe metabolism of Niludipine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Niludipine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Niludipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Niludipine can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Niludipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiflunisalNiludipine may increase the anticoagulant activities of Diflunisal.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Niludipine.Approved, Investigational
DiltiazemThe metabolism of Niludipine can be decreased when combined with Diltiazem.Approved, Investigational
DisopyramideThe metabolism of Niludipine can be decreased when combined with Disopyramide.Approved
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Niludipine.Approved
DofetilideThe metabolism of Dofetilide can be decreased when combined with Niludipine.Approved, Investigational
DoxacuriumNiludipine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Niludipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Niludipine.Approved, Investigational
DoxycyclineThe metabolism of Niludipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Niludipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Niludipine.Approved, Vet Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Niludipine.Approved
EfavirenzThe serum concentration of Niludipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Niludipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Niludipine.Approved, Investigational
EnzalutamideThe serum concentration of Niludipine can be decreased when it is combined with Enzalutamide.Approved
ErgocalciferolThe metabolism of Niludipine can be decreased when combined with Ergocalciferol.Approved, Nutraceutical
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Niludipine.Approved
ErythromycinThe metabolism of Niludipine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololThe risk or severity of bradycardia can be increased when Niludipine is combined with Esmolol.Approved
EtoposideThe metabolism of Niludipine can be increased when combined with Etoposide.Approved
EtravirineThe serum concentration of Niludipine can be decreased when it is combined with Etravirine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Niludipine.Experimental
FluconazoleThe metabolism of Niludipine can be decreased when combined with Fluconazole.Approved, Investigational
FlunisolideThe metabolism of Niludipine can be increased when combined with Flunisolide.Approved, Investigational
Fluocinolone acetonideThe metabolism of Niludipine can be increased when combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Niludipine.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Niludipine.Experimental
FluvastatinThe metabolism of Niludipine can be increased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Niludipine can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Niludipine.Approved, Nutraceutical, Vet Approved
FosamprenavirThe metabolism of Niludipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Niludipine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Niludipine.Approved, Investigational
Fusidic AcidThe serum concentration of Niludipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinGabapentin may increase the bradycardic activities of Niludipine.Approved, Investigational
GallamineNiludipine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideNiludipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Niludipine.Approved, Investigational
HexobarbitalThe metabolism of Niludipine can be increased when combined with Hexobarbital.Approved
HydrocortisoneThe metabolism of Niludipine can be increased when combined with Hydrocortisone.Approved, Vet Approved
IcosapentThe risk or severity of hyperkalemia can be increased when Icosapent is combined with Niludipine.Approved, Nutraceutical
IdelalisibThe metabolism of Niludipine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Niludipine.Approved
ImatinibThe metabolism of Niludipine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Niludipine.Approved
IndomethacinThe risk or severity of hyperkalemia can be increased when Indomethacin is combined with Niludipine.Approved, Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Niludipine.Withdrawn
IsavuconazoleThe serum concentration of Niludipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Niludipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Niludipine.Approved
IsoniazidThe metabolism of Niludipine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Niludipine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Niludipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Niludipine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Niludipine can be decreased when combined with Ketoconazole.Approved, Investigational
KetorolacThe risk or severity of hyperkalemia can be increased when Ketorolac is combined with Niludipine.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Niludipine.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Niludipine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Niludipine.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Niludipine.Approved
LiothyronineThe metabolism of Niludipine can be decreased when combined with Liothyronine.Approved, Vet Approved
LopinavirThe metabolism of Niludipine can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Niludipine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Lovastatin can be decreased when combined with Niludipine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Niludipine.Approved, Investigational
LuliconazoleThe serum concentration of Niludipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Niludipine can be increased when combined with Lumacaftor.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Niludipine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Niludipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Niludipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Niludipine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Niludipine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Niludipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Niludipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Niludipine.Approved, Investigational
Medroxyprogesterone acetateThe metabolism of Niludipine can be increased when combined with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe metabolism of Niludipine can be decreased when combined with Medrysone.Approved
MesalazineNiludipine may increase the anticoagulant activities of Mesalazine.Approved
MethohexitalThe metabolism of Niludipine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Niludipine.Approved, Investigational
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Niludipine.Approved
MethylphenobarbitalThe metabolism of Niludipine can be increased when combined with Methylphenobarbital.Approved
MetocurineNiludipine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideNiludipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MibefradilThe metabolism of Niludipine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Niludipine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidodrineNiludipine may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Niludipine can be increased when it is combined with Mifepristone.Approved, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Niludipine.Approved, Vet Approved
MitotaneThe serum concentration of Niludipine can be decreased when it is combined with Mitotane.Approved
MivacuriumNiludipine may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Niludipine can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe therapeutic efficacy of Niludipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaloxoneThe metabolism of Niludipine can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe risk or severity of hyperkalemia can be increased when Naproxen is combined with Niludipine.Approved, Vet Approved
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Niludipine.Approved, Withdrawn
NelfinavirThe metabolism of Niludipine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Niludipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Niludipine can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Niludipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Niludipine.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Niludipine.Experimental
NilotinibThe metabolism of Niludipine can be decreased when combined with Nilotinib.Approved, Investigational
NitroprussideNiludipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorgestimateThe metabolism of Niludipine can be increased when combined with Norgestimate.Approved, Investigational
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Niludipine.Approved
OctreotideOctreotide may increase the bradycardic activities of Niludipine.Approved, Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Niludipine.Approved, Investigational
OlaparibThe metabolism of Niludipine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of hyperkalemia can be increased when Olmesartan is combined with Niludipine.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Niludipine.Experimental
OsimertinibThe serum concentration of Niludipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe metabolism of Niludipine can be increased when combined with Oxiconazole.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Niludipine.Investigational, Withdrawn
PalbociclibThe serum concentration of Niludipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Niludipine.Approved
PancuroniumNiludipine may increase the neuromuscular blocking activities of Pancuronium.Approved
PantoprazoleThe metabolism of Niludipine can be increased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Niludipine can be decreased when combined with Paroxetine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Niludipine can be decreased when used in combination with Patent Blue.Approved
PegvisomantThe metabolism of Niludipine can be increased when combined with Pegvisomant.Approved
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Niludipine.Experimental
PentobarbitalThe metabolism of Niludipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Niludipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Niludipine.Approved, Withdrawn
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Niludipine.Approved
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Niludipine.Approved
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Niludipine.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Niludipine.Approved
PipecuroniumNiludipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PitolisantThe serum concentration of Niludipine can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Niludipine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Niludipine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Niludipine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Niludipine.Experimental
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Niludipine.Approved, Vet Approved
PosaconazoleThe metabolism of Niludipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Niludipine.Approved, Investigational
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Niludipine.Approved
PregabalinNiludipine may increase the bradycardic activities of Pregabalin.Approved, Illicit, Investigational
PrimidoneThe metabolism of Niludipine can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Niludipine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Niludipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Niludipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Niludipine.Approved, Investigational
PropranololThe risk or severity of bradycardia can be increased when Niludipine is combined with Propranolol.Approved, Investigational
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Niludipine.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Niludipine.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Niludipine.Approved, Investigational
QuinineThe metabolism of Niludipine can be increased when combined with Quinine.Approved
RamiprilThe risk or severity of hyperkalemia can be increased when Ramipril is combined with Niludipine.Approved
RanolazineThe metabolism of Niludipine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumNiludipine may increase the neuromuscular blocking activities of Rapacuronium.Approved, Withdrawn
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Niludipine.Investigational
RifampicinThe metabolism of Niludipine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Niludipine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Niludipine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Niludipine can be increased when combined with Rifaximin.Approved, Investigational
RimexoloneThe metabolism of Niludipine can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Niludipine.Approved, Investigational
RitonavirThe metabolism of Niludipine can be decreased when combined with Ritonavir.Approved, Investigational
RocuroniumNiludipine may increase the neuromuscular blocking activities of Rocuronium.Approved
SaquinavirThe metabolism of Niludipine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Niludipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Niludipine can be increased when combined with Secobarbital.Approved, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Niludipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Niludipine.Approved, Investigational
SildenafilThe metabolism of Sildenafil can be decreased when combined with Niludipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Niludipine.Approved
SiltuximabThe serum concentration of Niludipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Niludipine can be increased when it is combined with Simeprevir.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Niludipine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Niludipine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Niludipine.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Niludipine.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Niludipine.Approved
St. John's WortThe serum concentration of Niludipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Niludipine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineThe risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Niludipine.Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Niludipine.Approved
SulfanilamideThe metabolism of Niludipine can be decreased when combined with Sulfanilamide.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Niludipine.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Niludipine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Niludipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Niludipine can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Niludipine can be decreased when combined with Temazepam.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Niludipine.Approved
TerbinafineThe metabolism of Niludipine can be increased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Niludipine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Niludipine.Approved
ThiamylalThe metabolism of Niludipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Niludipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Niludipine.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Niludipine.Approved, Withdrawn
TiclopidineThe metabolism of Niludipine can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of bradycardia can be increased when Niludipine is combined with Timolol.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Niludipine.Approved
TipranavirThe metabolism of Niludipine can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Niludipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Niludipine.Approved, Vet Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Niludipine.Approved, Investigational
TriamcinoloneThe metabolism of Niludipine can be increased when combined with Triamcinolone.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Niludipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Niludipine.Experimental
TrimethoprimThe risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Niludipine.Approved, Vet Approved
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Niludipine.Approved
TroleandomycinThe metabolism of Niludipine can be decreased when combined with Troleandomycin.Approved
TubocurarineNiludipine may increase the neuromuscular blocking activities of Tubocurarine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Niludipine.Investigational
ValsartanThe risk or severity of hyperkalemia can be increased when Valsartan is combined with Niludipine.Approved, Investigational
VecuroniumNiludipine may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Niludipine.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Niludipine.Approved
VoriconazoleThe metabolism of Niludipine can be decreased when combined with Voriconazole.Approved, Investigational
ZincThe therapeutic efficacy of Zinc can be decreased when used in combination with Niludipine.Approved, Investigational
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Niludipine.Approved
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Niludipine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
89767
PubChem Substance
310265143
ChemSpider
81025
ChEMBL
CHEMBL2106840
Wikipedia
Niludipine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00375 mg/mLALOGPS
logP4.18ALOGPS
logP3.48ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)19.46ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area126.23 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity131.79 m3·mol-1ChemAxon
Polarizability52.64 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Dialkyl ethers / Dialkylamines
show 7 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Amino acid or derivatives
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on October 23, 2015 11:04 / Updated on August 26, 2018 02:04